Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Royalty - LARVOL DELTA

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era. (PubMed, Lancet Oncol) - "The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape."

Checkpoint inhibition • IO biomarker • Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy (ESMO 2026) - No abstract available

Metastases • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

First results of SWOG S2200, a randomized, phase II study comparing cabozantinib with or without atezolizumab in metastatic papillary renal cell carcinoma (mPRCC) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Genito-urinary Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

No Single Radiotracer Tells the Whole Story: A Multitracer PET/CT Case in Medullary Thyroid Carcinoma (EANM 2026) - "Materials and A 59-year-old male with metastatic medullary thyroid carcinoma (MTC), previously treated with 177Lu-DOTATATE, stereotactic body radiation therapy (SBRT), vandetanib, and cabozantinib, was referred to our department for evaluation of molecular imaging and radioligand therapy (RLT) following biochemical progression, indicated by rising calcitonin and carcinoembryonic antigen (CEA) levels during treatment... This case illustrates how a single PET radiotracer can overlook clinically significant disease in metastatic medullary thyroid cancer (MTC). By integrating SSTR, 18F-DOPA, 18F-FDG, and 68Ga-FAPI PET/CT, we uncovered significant lesion-level heterogeneity and identified FAPI-targeted therapy as the most pertinent next theranostic option. For selected, heavily pretreated MTC patients, a customized multitracer approach may offer a more comprehensive understanding of disease biology and facilitate more personalized treatment decisions."

Clinical • Hepatology • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CEACAM5 • SSTR

[¹⁶¹Tb]Tb-CP04 for CCK2R-Targeted Radioligand Therapy in Advanced Medullary Thyroid Carcinoma: First-in-Human Study Design (Acronim MTC-Tb) (EANM 2026) - "Currently approved multikinase inhibitors, such as cabozantinib and vandetanib, provide temporary disease control without a clear overall survival benefit. Although selpercatinib has demonstrated high efficacy in patients with RET-mutated MTC, this subgroup counts for only about 25% of cases, leaving the majority of patients without access to effective targeted therapies... Radioligand therapy with [¹⁶¹Tb]Tb-CP04 represents a promising targeted treatment strategy for patients with advanced, inoperable MTC. Its radiophysical properties may enable improved tumor control with acceptable toxicity, addressing an unmet clinical need."

First-in-human • Metastases • P1 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CCKBR • GAST • RET

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (clinicaltrials.gov) - P2 | N=98 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2026 ➔ Sep 2027

Trial completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Medullary Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - "The event will highlight new data from the ARC-20 platform study, which is evaluating casdatifan, a next-generation HIF-2α inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (ccRCC). Featured presenters will include members of the Arcus management team and Dr. Rana McKay...who is a leading academic expert in the treatment of kidney cancer with deep experience using HIF-2α inhibitors."

Announcement

Exceptional response to sequential TRK inhibition in an epithelioid glioblastoma with NOS1AP-NTRK1 fusion (EANO 2026) - "First-line therapy consisted of standard radiochemotherapy with concomitant and adjuvant temozolomide from April to October 2021...Lomustine + bevacizumab was ineffective (PFS: 2 months)... Sequential NTRK-targeted therapy can produce exceptional and durable responses in NTRK1 fusion-positive eGB. Larotrectinib was initiated after progression based on the presence of a NOS1AP-NTRK1 fusion, targeting constitutive TRKA activation and downstream MAPK and PI3K-AKT signaling, resulting in rapid antitumor effects. Upon progression, repotrectinib, a CNS-penetrant second-generation TRK inhibitor, was selected to overcome potential resistance mutations and maintain pathway inhibition."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • BRAF • NTRK • NTRK1

Updated Results of Randomized Phase 3 Study of Selpercatinib vs Cabozantinib or Vandetanib (C/V) in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer (MTC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. (PubMed, J Clin Oncol) - P1/2 | "At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/vandetanib-naïve MTC and 95.8% among patients with treatment-naïve TC...The safety profile of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatment-naïve and previously treated patients with RET-mutant MTC and RET fusion-positive TC."

Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Impact of Neoadjuvant TKI Therapy on Tumor Reduction and Resectability in Locally Advanced Thyroid Carcinoma (ETA 2026) - "Therapies included selective (dabrafenib/trametinib, entrectinib, larotrectinib, selpercatinib) and multikinase inhibitors (lenvatinib, cabozantinib, vandetanib)... Neoadjuvant TKI therapy demonstrated promising results in locally advanced thyroid carcinoma, achieving high disease control rates and enabling surgical resection in over one-third of cases. Outcomes were comparable between selective and multikinase TKIs, and meaningful responses were observed across histological subtypes, although survival remained significantly longer in differentiated tumors. These findings, representing one of the largest single-center cohorts, reinforce the growing role of neoadjuvant therapy in multidisciplinary management of advanced thyroid cancer."

Clinical • Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. (PubMed, Oral Oncol) - "Cetuximab plus cabozantinib demonstrated a manageable toxicity profile and preliminary efficacy in patients with heavily treated R/M HNSCC. The combination of cetuximab with MKIs targeting the AXL/MET/VEGFR axis warrants further investigation, including in cetuximab-naïve patients."

Journal • Metastases • P1 data • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • AXL

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. (PubMed, N Engl J Med) - P3 | "Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.)."

Journal • Metastases • P3 data • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

From Cure to Recurrence: Very Early Metastatic Hepatocellular Carcinoma After Living Donor Liver Transplantation (ACG 2026) - "Sequential TKI therapy with lenvatinib and cabozantinib was limited by progression and toxicity. With AFP now >500 ng/mL, ramucirumab or regorafenib are under consideration...(B) Pankeratin (panCK) immunostain highlighting tumor cells. Original magnification Ã500."

Metastases • Cardiovascular • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Portal Hypertension • Solid Tumor • Transplantation

Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (ESMO 2023) - P3 | "This study highlights the importance of selectivity in targeting RET-mutant MTC. Selpercatinib should be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC."

Clinical • Late-breaking abstract • Metastases • P3 data • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

OPTIMAL SECOND-LINE TREATMENT AFTER DURVALUMAB PLUS TREMELIMUMAB FOR ADVANCED HEPATOCELLULAR CARCINOMA: IMPACT OF FIRST-LINE TUMOR RESPONSE ON TREATMENT SELECTION (UEGW 2026) - "Sixty-six patients (63.5%) proceeded to second-line therapy, including atezolizumab plus bevacizumab (Atez/Bev, n=30), lenvatinib (LEN, n=33), and cabozantinib (CAB, n=3)... Transition to second-line therapy after Dur/Tre was associated with significantly improved survival, highlighting the importance of preserved liver function. Moreover, treatment response to first-line therapy may help stratify the optimal choice of second-line regimen."

Clinical • Metastases • Addiction (Opioid and Alcohol) • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

CHOLESTASIS FOLLOWING IMMUNOTHERAPY: IMMUNE-MEDIATED INJURY OR DIRECT DRUG-INDUCED LIVER INJURY? THE IMPORTANCE OF LIVER BIOPSY IN DISTINGUISHING BETWEEN THE TWO (UEGW 2026) - "Given the suspicion of immune-mediated liver injury, prednisone 1 mg/kg was initiated, but there was no improvement; a percutaneous liver biopsy was then performed, which showed severe loss of interlobular bile ducts, without ductular reaction or cholangitis and moderated amount of cholestasis, in kupffer cells and hepatocytes, consistent with Vanishing syndrome. Based on the pattern of injury, the condition was attributed to nivolumab, and ursodeoxycholic acid 10 mg/kg/day was initiated, resulting in partial improvement of serum liver enzymes in two days (AST 128 U/L / ALT 88 U/L / AP 498 U/L / GGT 653 U/L / total bilirubin 20 mg/dL / direct fraction 15 mg/dL).Vanishing syndrome is a rare condition characterized by progressive ductopenia, resulting in persistent colitis (1). It may be associated with chemotherapy through mechanisms of direct toxicity and immune-mediated response (2). This report presents a relevant hypothesis that should be considered in patients with..."

Biopsy • Cholestasis • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hepatology • Immunology • Liver Failure • Solid Tumor

Systemic Therapy for Advanced Hepatocellular Carcinoma with Impaired Liver Function: Navigating the Evidence Gap. (PubMed, Cancers (Basel)) - "Cohort 5 of the CheckMate 040 nivolumab trial included selected patients with CTP-B7/B8 disease and demonstrated modest efficacy, with an objective response rate of 12% and a median overall survival of 7.6 months. Additionally, the phase 3b single-arm SIERRA study reported a manageable safety profile for durvalumab plus tremelimumab (STRIDE regimen) in the CTP-B population. In contrast, regimens incorporating vascular endothelial growth factor (VEGF) inhibition, such as atezolizumab-bevacizumab and tyrosine kinase inhibitors (TKIs), may require cautious use due to an increased risk of bleeding or hepatic decompensation. TKIs, including sorafenib, lenvatinib, regorafenib, and cabozantinib, are metabolized by hepatic CYP450 pathways and require careful patient selection, monitoring, and dose optimization...Decreased liver reserve represents a heterogeneous clinical state, and treatment benefits depend on maintaining treatment duration without precipitating hepatic..."

Journal • Review • Cardiovascular • CNS Disorders • Fibrosis • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Liver Failure • Oncology • Portal Hypertension • Solid Tumor

Pooled Individual Patient-Data Analysis of Clinical Trials on Second-line Multikinase Inhibitors Following Immunotherapy in Hepatocellular Carcinoma. (PubMed, JHEP Rep) - "The current study provides the largest prospective data on second-line MKIs in patients with HCC who had prior first-line immunotherapy. Given the strong prognostic signal of MVI observed in this analysis, our data suggest considering MVI, rather than prior response to immunotherapy or EHS, as a stratification factor for future second-line trials."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents. (PubMed, Int J Mol Sci) - "The clinical effectiveness of c-Met-targeted treatments such as crizotinib, capmatinib, tepotinib, savolitinib, and cabozantinib has confirmed c-Met as a viable oncogenic driver for therapy, leading to the development of various next-generation inhibitors with different structures...In addition, recent advances in dual- and multitarget agents that simultaneously modulate c-Met and complementary therapeutic targets, including VEGFR-2, EGFR, AXL, MER, PARP1, CDK2, and tubulin, are highlighted as promising strategies for overcoming pathway redundancy and acquired resistance. This review summarizes contemporary structure-based and medicinal chemistry principles underlying c-Met inhibitor discovery, critically evaluates the relationship between biochemical potency and therapeutic efficacy, and provides a framework for the rational design of next-generation c-Met-targeted and multitarget anticancer agents."

Journal • Review • Oncology • Solid Tumor • AXL • CDK2 • EGFR • KDR • PARP1

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Sep 2027

Trial completion date • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Targeted Colorectal Cancer Therapy Using Cabozantinib-Loaded PLGA Nanoparticles: Formulation, Cytotoxicity, and Molecular Docking Analysis. (PubMed, Chemistry) - "The HET-CAM assay demonstrated remarkable anti-inflammatory effects, with 72.38% ± 1.89% vessel inhibition. This nanoparticle strategy overcomes pharmacokinetic pitfalls of CBZT, which holds promise for targeted colorectal cancer therapeutics, and perhaps beyond."

Journal • Colorectal Cancer • Oncology • Solid Tumor • BCL2

International Metastatic RCC Database Consortium (IMDC) risk–stratified outcomes with first line cabozantinib plus nivolumab (CaboNivo) in advanced renal cell carcinoma (aRCC): CaboCombo subgroup analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Synergistic potential of Cabozantinib and Radiotherapy in advanced Renal Cell Carcinoma: updated survival outcomes from a multicentre analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor